Trials / Completed
CompletedNCT03440385
Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 606 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ozanimod | Specified dose on specified days |
| OTHER | Placebo | Specified dose on specified days |
Timeline
- Start date
- 2018-03-07
- Primary completion
- 2023-11-21
- Completion
- 2023-11-21
- First posted
- 2018-02-22
- Last updated
- 2024-12-05
- Results posted
- 2024-12-05
Locations
368 sites across 31 countries: United States, Australia, Austria, Bulgaria, Canada, China, Colombia, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Israel, Lithuania, Netherlands, Poland, Portugal, Russia, Senegal, Serbia, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Taiwan, Turkey (Türkiye), Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03440385. Inclusion in this directory is not an endorsement.